Wedbush analyst Robert Driscoll maintains Elevation Oncology (NASDAQ:ELEV) with a Outperform and raises the price target from $5 to $8.
Wedbush Maintains Outperform on Elevation Oncology, Raises Price Target to $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.